- American City Business Journals•19 days ago
Hemispherx Biopharma Inc. entered into definitive agreements with several institutional investors under which the Philadelphia biotechnology company will receive gross proceeds of about $1 million through a sale of its common stock. Last week, Hemispherx announced that an order of newly manufactured Ampligen for sale using an Early Access Program to benefit patients suffering with chronic fatigue syndrome and pancreatic cancer in Europe had been shipped. In a letter to shareholders earlier this week, Hemispherx CEO Thomas K. Equels said the company expects to continue its discussions with the Food and Drug Administration to “identify a path forward” for Ampligen as a treatment for chronic fatigue syndrome.
- GlobeNewswire•20 days ago
PHILADELPHIA, Feb. 02, 2017-- Hemispherx Biopharma, Inc., announced today that it has entered into definitive agreements with several institutional investors for an offering of shares of common stock with ...
- GlobeNewswire•27 days agoHemispherx Announces First Shipment of Newly Manufactured Rintatolimod (Ampligen®) for Sale to Early Access Program in Europe
PHILADELPHIA, Jan. 26, 2017-- Hemispherx Biopharma announced today that an order of newly manufactured rintatolimod for sale utilizing the Early Access Program in Europe has been shipped with receipt confirmed ...
HEB : Summary for Hemispherx BioPharma, Inc. Comm - Yahoo Finance
Hemispherx Biopharma, Inc. (HEB)
NYSE MKT - NYSE MKT Delayed Price. Currency in USD
Add to watchlist
|Day's Range||0.46 - 0.52|
|52 Week Range||0.39 - 2.64|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-1.07|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|